查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1503341

2030 年微射流市场预测：按产品类型、材料、技术、应用、最终用户和地区进行的全球分析

Microfluidics Market Forecasts to 2030 - Global Analysis By Product Type (Microfluidic-Based Devices, Microfluidic Components and Other Product Types), Material, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2024 年全球微射流市场规模将达到 256 亿美元，预计到 2030 年将达到 593 亿美元，预测期内复合年增长率为 15.0%。

微射流工程是一个跨学科领域，涉及微製造设备中微升或纳升规模的少量流体的精确控制和操纵。这些设备有时被称为实验室晶片系统，整合了流道、阀门、泵浦和感测器等各种组件，以实现流体的精确处理、混合和分析。微射流设备在医疗诊断、疾病检测、生物标记监测和药物传递方面也发挥着重要作用。微射流所提供的小型化、自动化和多功能性已经彻底改变了科学研究，并有可能在未来对各种行业产生重大影响。

对照护现场(POC) 诊断的需求不断增长

POC 诊断需要紧凑、高效且经济高效的解决方案，能够在患者所在地提供快速、准确的结果，并减少对密集实验室测试的需求。可以操纵少量液体的微射流技术完美地满足了这些需求。微射流技术提高了诊断测试的灵敏度和速度，同时允许以便携式格式多重分析和整合复杂的测定。这种需求正在推动微射流设备的创新和投资，从而推动实验室晶片技术和整合诊断平台的进步。因此，微射流市场正在经历强劲成长。

微射流设计与操作的复杂性

设计微射流系统需要先进的工程和精密製造技术，这是昂贵且耗时的。这种复杂性通常会导致製造成本增加，使得微射流装置与传统诊断方法相比在经济上没有吸引力。此外，微射流操作的复杂性需要专门的知识和技术，这可能需要大量的培训并限制普及。此外，将微射流系统整合到现有的实验室基础设施中并确保其可靠性和可重复性可能是一项挑战。

科技的进步与应用的扩展

微加工技术、材料科学和数位技术整合的创新提高了微射流的精度、效率和功能。这些进步使得先进的实验室晶片系统的开发成为可能，该系统可以高精度、高速度地执行复杂的生化分析。微射流工程在医疗诊断、药物传输、环境监测和食品安全等领域的广泛应用正在扩大其市场范围。

监管审批流程漫长而复杂

对医疗设备的严格监管要求，尤其是涉及新技术的医疗器械，可能会导致核准时间延长并增加製造商的成本。这种延迟可能会延迟创新微射流解决方案的上市时间，降低竞争力，并阻碍及时获得先进的诊断和治疗方法。此外，应对复杂的监管环境需要大量资源和专业知识，这对于小型企业和新兴企业来说尤其具有挑战性。

COVID-19 的影响

能够有效处理少量液体的微射流设备对于开发快速照护现场COVID-19 测试至关重要。此次疫情加速了微射流技术的创新和投资，以满足对可扩展且经济高效的诊断解决方案的高需求。此外，人们对快速诊断重要性的认识不断增强，微射流技术的应用范围已扩展到 COVID-19 之外，并促进其在感染疾病中的广泛采用。

基于微射流的设备领域预计将在预测期内成为最大的领域

基于微射流的设备预计将在预测期内成长最快，因为它们能够精确控制少量流体，以实现高通量筛检、快速诊断和高效的药物输送系统。将多种实验室功能整合到单一晶片上的能力可以降低成本并提高各种应用的便携性和效率，包括医疗诊断、环境监测和药物研究。实验室晶片技术的兴起，促进了照护现场快速、准确的测试，就体现了这种影响。

预计硅细分市场在预测期间内复合年增长率最高

由于微加工精度高、坚固性和生物相容性等优异的材料特性，硅细分市场预计在预测期内将表现出最高的复合年增长率。在微射流装置的製造中使用硅可以创建对于诊断、药物传输和生物研究应用至关重要的复杂且可靠的结构。硅的导热性和电特性有利于整合感测器和电子元件。然而，基于硅的製造成本高、复杂性高，这会限制可访问性和扩充性。

比最大的地区

北美拥有完善的医疗保健系统，一般人群越来越多地采用新疗法，该地区人口中感染疾病和慢性病的患病率预计将在预测期内占据最大的市场占有率。此外，癌症负担的增加预计也将推动对微射流工程的需求。例如，2024年1月，美国癌症协会估计，2024年美国将有超过200万人被诊断出罹患癌症，高于2023年的190万人。因此，该国癌症发病率的上升预计将推动微射流工程的需求并推动市场成长。

复合年增长率最高的地区：

由于对可携式和具有成本效益的诊断设备的需求不断增长、微加工技术的进步以及政府支持该地区研发的倡议，预计亚太地区将在预测期内保持最高的复合年增长率。由于强大的製造能力和对医疗基础设施的投资，中国、日本和韩国等国家处于市场成长的前沿。此外，学术机构和产业相关人员之间的合作正在推动微射流技术的创新。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球微射流市场：依产品类型

  • 基于微射流的设备
  • 微射流元件
  • 其他产品类型

第六章全球微射流市场：依材料分类

  • 聚合物
    • 聚甲基丙烯酸甲酯（PMMA）
    • 聚二甲基硅氧烷 (PDMS)
  • 玻璃
  • 硅
  • 其他材料

第七章全球微射流市场：依技术分类

  • 微型帮浦
  • 微射流晶片
  • 微型针
  • 微搅拌机
  • 微型阀
  • 其他技术

第八章全球微射流市场：依应用分类

  • 体外诊断（IVD）
  • 药物发现与临床诊断
  • 就地检验(POCT)
  • 基因组学和蛋白​​质组学
  • 基于细胞的检测
  • 实验室晶片和晶片器官
  • 植入式装置
  • 其他用途

第九章全球微射流市场：依最终用户分类

  • 医院和诊断中心
  • 学术研究所
  • 製药和生物技术公司
  • 其他最终用户

第十章全球微射流市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第十一章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十二章 公司概况

  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Perkinelmer, Inc.
  • Danaher
  • Life Technologies Corporation
  • Bio-Rad Laboratories, Inc.
  • Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Fluidigm Corporation
  • Qiagen NV
  • Thermo Fischer Scientific
  • Biomerieux
  • Cellix Ltd.
  • Elveflow
  • Micronit Micro Technologies BV
  • Standard BioTools
  • UFluidix
  • Emulate Inc.
  • Dolomite Microfluidics
  • Sphere Fluidics Limited
Product Code: SMRC26507

According to Stratistics MRC, the Global Microfluidics Market is accounted for $25.6 billion in 2024 and is expected to reach $59.3 billion by 2030 growing at a CAGR of 15.0% during the forecast period. Microfluidics is a multidisciplinary field that deals with the precise control and manipulation of small volumes of fluids, typically on the microliter or nanoliter scale, within microfabricated devices. These devices, often referred to as lab-on-a-chip systems, integrate various components such as channels, valves, pumps, and sensors, allowing for the precise handling, mixing, and analysis of fluids. Microfluidic devices also play a crucial role in medical diagnostics, enabling the detection of diseases, monitoring of biomarkers, and drug delivery. The miniaturization, automation, and versatility offered by microfluidics have revolutionized scientific research and have the potential to significantly impact various industries in the future.

Market Dynamics:

Driver:

Rising demand for point-of-care (POC) diagnostics

POC diagnostics require compact, efficient, and cost-effective solutions to deliver quick and accurate results at the patient's location, reducing the need for centralized laboratory testing. Microfluidic technologies, with their capability to manipulate small volumes of fluids, perfectly meet these requirements. They enhance the sensitivity and speed of diagnostic tests while enabling multiplexing and integration of complex assays in portable formats. This demand is driving innovations and investments in microfluidic devices, leading to advancements in lab-on-a-chip technologies and integrated diagnostic platforms. As a result, the microfluidics market is experiencing robust growth.

Restraint:

Complexity of microfluidic design and operation

Designing microfluidic systems requires sophisticated engineering and precise fabrication techniques, which can be costly and time-consuming. These complexities often lead to higher production costs, making microfluidic devices less economically attractive compared to traditional diagnostic methods. Additionally, the intricate nature of microfluidic operations demands specialized knowledge and skills, potentially limiting widespread adoption in clinical and research settings due to the necessity for extensive training. Moreover, integrating microfluidic systems with existing laboratory infrastructure and ensuring their reliability and reproducibility can be challenging.

Opportunity:

Technological advancements and expanding applications

Innovations in microfabrication techniques, material sciences, and integration of digital technologies have enhanced the precision, efficiency, and functionality of microfluidic devices. These advancements enable the development of sophisticated lab-on-a-chip systems capable of performing complex biochemical analyses with high accuracy and speed. The expanding applications of microfluidics in areas such as medical diagnostics, drug delivery, environmental monitoring, and food safety are broadening its market scope.

Threat:

Lengthy and complex regulatory approval process

Stringent regulatory requirements for medical devices, particularly those involving new technologies, can lead to prolonged approval timelines and increased costs for manufacturers. These delays can slow down the time-to-market for innovative microfluidic solutions, reducing their competitive advantage and hindering timely access to advanced diagnostics and treatment options. Additionally, navigating the complex regulatory landscape requires substantial resources and expertise, which can be particularly challenging for smaller companies and startups.

Covid-19 Impact

Microfluidic devices, with their ability to process small fluid volumes efficiently, became crucial for developing quick, point-of-care COVID-19 tests. The pandemic accelerated innovations and investments in microfluidic technologies to meet the high demand for scalable and cost-effective diagnostic solutions. Additionally, the heightened awareness of the importance of quick diagnostics has expanded the applications of microfluidics beyond COVID-19, promoting broader adoption in infectious di

The microfluidic-based devices segment is expected to be the largest during the forecast period

The microfluidic-based devices is expected to be the largest during the forecast period as these devices offer precise control over small fluid volumes, enabling high-throughput screening, rapid diagnostics, and efficient drug delivery systems. Their ability to integrate multiple laboratory functions on a single chip reduces costs and enhances portability and efficiency in various applications, including medical diagnostics, environmental monitoring, and pharmaceutical research. The rise of lab-on-a-chip technologies exemplifies this impact, facilitating quick, accurate testing at the point-of-care.

The silicon segment is expected to have the highest CAGR during the forecast period

The silicon segment is expected to have the highest CAGR during the forecast period due to its excellent material properties, including high precision in microfabrication, robustness, and biocompatibility. Silicon's use in manufacturing microfluidic devices enables the creation of intricate and reliable structures essential for applications in diagnostics, drug delivery, and biological research. Its thermal conductivity and electrical properties are beneficial for integrating sensors and electronic components. However, the high cost and complexity of silicon-based fabrication can limit accessibility and scalability.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to factors such as the well-established healthcare system, the higher adoption of novel therapeutics among the general population, and the increasing prevalence of infectious and chronic diseases among the region's population. Moreover the rising burden of cancer is also expected to fuel the demand for microfluidics. For instance, in January 2024, according to the American Cancer Society, it was estimated that more than 2.0 million cancer cases would be diagnosed in the United States in 2024, an increase from 1.9 million cancer cases in 2023. Hence, the country's growing burden of cancer is expected to fuel the demand for microfluidics and favor market growth.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period owing to rising demand for portable and cost-effective diagnostic devices, advancements in microfabrication technologies, and government initiatives supporting research and development in the region. Countries like China, Japan, and South Korea are at the forefront of market growth, fueled by their strong manufacturing capabilities and investments in healthcare infrastructure. Additionally, collaborations between academic institutions and industry players are fostering innovation in microfluidics technology.

Key players in the market

Some of the key players in Microfluidics market include Illumina, Inc., Agilent Technologies, Inc., Perkinelmer, Inc., Danaher, Life Technologies Corporation, Bio-Rad Laboratories, Inc., Hoffmann-La Roche Ltd, Abbott Laboratories, Fluidigm Corporation, Qiagen N.V., Thermo Fischer Scientific, Biomerieux, Cellix Ltd., Elveflow, Micronit Micro Technologies B.V., Standard BioTools, UFluidix, Emulate Inc., Dolomite Microfluidics and Sphere Fluidics Limited

Key Developments:

In June 2024, Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost. XLEAP-SBS chemistry is a faster, higher quality, and more robust sequencing-by-synthesis chemistry that delivers approximately 20% faster turnaround times.

In June 2024, Agilent Announces Cutting-Edge Advances in GC/MS and LC/Q-TOF Technology at ASMS 2024. These instruments exemplify Agilent's unwavering commitment to advancing scientific discovery through innovative instrumentation, significantly shaping the landscape of mass spectrometry.

In January 2024, Illumina expands collaboration with Janssen to advance molecular residual disease cancer test This collaboration will be the first relating to the development of Illumina's novel molecular residual disease (MRD) assay, a whole-genome sequencing.

Product Types Covered:

  • Microfluidic-Based Devices
  • Microfluidic Components
  • Other Product Types

Materials Covered:

  • Polymers
  • Glass
  • Silicon
  • Other Materials

Technologies Covered:

  • Micro Pumps
  • Microfluidic Chips
  • Micro Needles
  • Micro Mixers
  • Micro Valves
  • Other Technologies

Applications Covered:

  • In Vitro Diagnostics (IVD)
  • Drug Discovery & Clinical Diagnostics
  • Point-of-Care Testing (POCT)
  • Genomics & Proteomics
  • Cell-based Assays
  • Lab-on-a-chip & Organs-on-chips
  • Implantable Devices
  • Other Applications

End Users Covered:

  • Hospitals & Diagnostic Centers
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Microfluidics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Microfluidic-Based Devices
  • 5.3 Microfluidic Components
  • 5.4 Other Product Types

6 Global Microfluidics Market, By Material

  • 6.1 Introduction
  • 6.2 Polymers
    • 6.2.1 Polymethyl Methacrylate (PMMA)
    • 6.2.2 Polydimethylsiloxane (PDMS)
  • 6.3 Glass
  • 6.4 Silicon
  • 6.5 Other Materials

7 Global Microfluidics Market, By Technology

  • 7.1 Introduction
  • 7.2 Micro Pumps
  • 7.3 Microfluidic Chips
  • 7.4 Micro Needles
  • 7.5 Micro Mixers
  • 7.6 Micro Valves
  • 7.7 Other Technologies

8 Global Microfluidics Market, By Application

  • 8.1 Introduction
  • 8.2 In Vitro Diagnostics (IVD)
  • 8.3 Drug Discovery & Clinical Diagnostics
  • 8.4 Point-of-Care Testing (POCT)
  • 8.5 Genomics & Proteomics
  • 8.6 Cell-based Assays
  • 8.7 Lab-on-a-chip & Organs-on-chips
  • 8.8 Implantable Devices
  • 8.9 Other Applications

9 Global Microfluidics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Diagnostic Centers
  • 9.3 Academic & Research Institutes
  • 9.4 Pharmaceutical & Biotechnology Companies
  • 9.5 Other End Users

10 Global Microfluidics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Illumina, Inc.
  • 12.2 Agilent Technologies, Inc.
  • 12.3 Perkinelmer, Inc.
  • 12.4 Danaher
  • 12.5 Life Technologies Corporation
  • 12.6 Bio-Rad Laboratories, Inc.
  • 12.7 Hoffmann-La Roche Ltd
  • 12.8 Abbott Laboratories
  • 12.9 Fluidigm Corporation
  • 12.10 Qiagen N.V.
  • 12.11 Thermo Fischer Scientific
  • 12.12 Biomerieux
  • 12.13 Cellix Ltd.
  • 12.14 Elveflow
  • 12.15 Micronit Micro Technologies B.V.
  • 12.16 Standard BioTools
  • 12.17 UFluidix
  • 12.18 Emulate Inc.
  • 12.19 Dolomite Microfluidics
  • 12.20 Sphere Fluidics Limited

List of Tables

  • Table 1 Global Microfluidics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Microfluidics Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Microfluidics Market Outlook, By Microfluidic-Based Devices (2022-2030) ($MN)
  • Table 4 Global Microfluidics Market Outlook, By Microfluidic Components (2022-2030) ($MN)
  • Table 5 Global Microfluidics Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 6 Global Microfluidics Market Outlook, By Material (2022-2030) ($MN)
  • Table 7 Global Microfluidics Market Outlook, By Polymers (2022-2030) ($MN)
  • Table 8 Global Microfluidics Market Outlook, By Polymethyl Methacrylate (PMMA) (2022-2030) ($MN)
  • Table 9 Global Microfluidics Market Outlook, By Polydimethylsiloxane (PDMS) (2022-2030) ($MN)
  • Table 10 Global Microfluidics Market Outlook, By Glass (2022-2030) ($MN)
  • Table 11 Global Microfluidics Market Outlook, By Silicon (2022-2030) ($MN)
  • Table 12 Global Microfluidics Market Outlook, By Other Materials (2022-2030) ($MN)
  • Table 13 Global Microfluidics Market Outlook, By Technology (2022-2030) ($MN)
  • Table 14 Global Microfluidics Market Outlook, By Micro Pumps (2022-2030) ($MN)
  • Table 15 Global Microfluidics Market Outlook, By Microfluidic Chips (2022-2030) ($MN)
  • Table 16 Global Microfluidics Market Outlook, By Micro Needles (2022-2030) ($MN)
  • Table 17 Global Microfluidics Market Outlook, By Micro Mixers (2022-2030) ($MN)
  • Table 18 Global Microfluidics Market Outlook, By Micro Valves (2022-2030) ($MN)
  • Table 19 Global Microfluidics Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 20 Global Microfluidics Market Outlook, By Application (2022-2030) ($MN)
  • Table 21 Global Microfluidics Market Outlook, By In Vitro Diagnostics (IVD) (2022-2030) ($MN)
  • Table 22 Global Microfluidics Market Outlook, By Drug Discovery & Clinical Diagnostics (2022-2030) ($MN)
  • Table 23 Global Microfluidics Market Outlook, By Point-of-Care Testing (POCT) (2022-2030) ($MN)
  • Table 24 Global Microfluidics Market Outlook, By Genomics & Proteomics (2022-2030) ($MN)
  • Table 25 Global Microfluidics Market Outlook, By Cell-based Assays (2022-2030) ($MN)
  • Table 26 Global Microfluidics Market Outlook, By Lab-on-a-chip & Organs-on-chips (2022-2030) ($MN)
  • Table 27 Global Microfluidics Market Outlook, By Implantable Devices (2022-2030) ($MN)
  • Table 28 Global Microfluidics Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 29 Global Microfluidics Market Outlook, By End User (2022-2030) ($MN)
  • Table 30 Global Microfluidics Market Outlook, By Hospitals & Diagnostic Centers (2022-2030) ($MN)
  • Table 31 Global Microfluidics Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 32 Global Microfluidics Market Outlook, By Pharmaceutical & Biotechnology Companies (2022-2030) ($MN)
  • Table 33 Global Microfluidics Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.